Business Wire

THE-OPEN-GROUP

Share
The Open Group: Hybrid Big Data Technologies Developed From €4.5M European Union Research Project Enter Final Industrial Evaluations

The Open Group , the vendor-neutral technology consortium, and the University of York today announced a partnership with a consortium of leading European research organizations, software developers, and industrial big data users. Together, they will make hybrid big data accessible and easy to integrate within new applications and services through developing and evolving next generation technologies.

With support from the European Union, the Polyglot and Hybrid Persistence Architectures for Big Data Analytics (TYPHON) project has already invested €4.5 million (US$5.3 million) into advanced technology development. This funding has enabled the rapid creation of applications that bridge the many formats and architectures used to store data today. The integrated platform is currently undergoing first deployments within major organizations across the Telecom, Banking, Automotive, and Aerospace industries, and is being made widely available in open source format. By implementing the new technologies, organizations are able to enhance the productivity of their data architects, reduce development time and costs, and deliver new applications and services that make full use of existing big data stores.

Today’s development teams face substantial challenges when it comes to ensuring hybrid big data applications and services are designed coherently, which requires capturing a range of different formats that data is held within. To overcome these complexities, the TYPHON project has built a set of tools for developing, querying, evolving, analyzing, and monitoring hybrid big data polystores. These polystores readily combine numerous types of underlying storage technologies, including relational, graph-based, document-based, natural language, and big data islands.

David Lounsbury, Chief Digital Officer, The Open Group said: “The TYPHON project has brought together a range of industry experts who have collaborated to streamline the time intensive process of implementing intricate big data solutions. By connecting many different storage formats, the new technologies enable developers to deliver applications capable of effectively utilizing big data assets within organizations. The Open Group has a long-standing history of working with the University of York on complex systems. Together, we can provide the expertise and guidance needed to drive these technologies through final industrial evaluations.”

The advanced tools provide big data systems developers with:

  • Technologies for designing hybrid polystores, taking into account the structure of the data, the availability, partitioning, and consistency requirements of different subsets of the data, and the available deployment resources
  • Novel algorithms for transforming hybrid polystore design models into preconfigured optimized virtual machines which can be deployed on cloud infrastructure
  • An extensible high-level language for querying and modifying data stored in hybrid polystores, as well as capabilities for translating high-level queries into efficient native queries
  • A high-performance framework for publishing and processing data access and updating events to facilitate real-time monitoring and predictive analytics
  • Technologies for evolving the organization and distribution of data in hybrid polystores, along with tools for monitoring use of polystores for enhanced evolution

Coordinated by The Open Group with technical leadership from the University of York, which has directed the advanced research, the TYPHON consortium includes:

“With the availability of the TYPHON Modelling Language, Query Language, Deployment Language, and tools for creating, monitoring, and evolving new hybrid big data polystores, software developers can now rapidly create next generation applications and systems,” said Professor Dimitris Kolovos, University of York. “Through addressing key industry challenges, the TYPHON project is dedicated to ensuring hybrid big data solutions are designed, assembled, and configured consistently - ultimately enabling organizations to unlock the power of data.”

The technological advances and innovations resulting from the TYPHON project, as well as the final versions of the technologies in open source format are publically available via the project website: www.typhon-project.org

The TYPHON project receives funding under the European Union Horizon 2020 Research and Innovation Programme, an initiative of the European Community created to foster European research and the development of new technologies, applications, and industries.

-ENDS-

About The Open Group

The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 800 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .

About the University of York

The Department of Computer Science at the University of York prepares graduates for the workplace at all levels through close collaboration with industry. The majority of the research work carried out has been classed as world-leading or internationally excellent and is focused around seven themes which align our academic strengths to best meet the greater scientific, social and environmental challenges of our time. Research teams work across disciplines within academia and industry with a strong focus placed on transforming research results into tangible solutions for industry. Further information on the University of York can be found at www.cs.york.ac.uk .

# # #

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye